News

F & GM's Deals With Micron: Is MU Stock Worth Buying Now?

MU, F, GM

Micron's Ford and GM supply deals, AI-driven HBM demand and tight memory supply strengthen its growth case after a sharp rally.

Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios

DHR, ISRG, BEAT, W, CSW

Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.

Is the Options Market Predicting a Spike in Expand Energy Stock?

EXE

Investors need to pay close attention to EXE stock based on the movements in the options market lately.

VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout

VRTX, CRNX, NBIX

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.

Do Options Traders Know Something About Embraer Stock We Don't?

EMBJ

Investors need to pay close attention to EMBJ stock based on the movements in the options market lately.

Major banks give their first ratings on SpaceX and they're quite bullish: 'Apex of civilizational ambition'

BLSH

Financial underwriters of SpaceX's IPO are now free to release their equity research.

There's a lot of 'noise' making it harder for investors to read the true state of the stock market

Rarely has so much attention been placed on the mechanical impact of index inclusion, policy-driven investment flows and options-hedging impact.

3 Stocks to Buy as Broker Ratings Upgrade Signals Growth Potential

ROK, UNFI, W

UNFI, ROK and W stand out as broker rating upgrades and upbeat earnings expectations signal growth potential amid uneven market gains.

5 Stocks With Recent Price Strength to Tap Market Rally

FLXS, ASX, TILE, APPS, AOUT

APPS, AOUT, FLXS, ASX and TILE surge on strong momentum, with sharp price gains and rising earnings estimates signaling potential for continued upside.

Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?

AZN, PFE, NVO, LLY

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.